CDMO

Avid Bioservices, Inc. [CDMO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CDMO Stock Summary

Top 10 Correlated ETFs

CDMO


Top 10 Correlated Stocks

CDMO


In the News

09:05 28 Mar 2024 CDMO

Why Is Avid Bioservices (CDMO) Stock Down 30% Today?

Avid Bioservices (NASDAQ: CDMO ) stock is falling on Thursday after the contract development and manufacturing company announced the pricing of a private placement. The private placement includes 7.00% Convertible Senior Notes due 2029 with an aggregate principal amount of $160 million.

02:58 28 Mar 2024 CDMO

Avid Bioservices: Don't Miss The Bigger Picture

Avid Bioservices has invested heavily in building new facilities, causing lower margins and negative free cash flow. The company's recent expansion projects have increased its revenue capacity to $400 million, with expected adjusted EBITDA margins in the low to mid 30s. Despite the investments, the company's guidance for the current fiscal year implies limited growth due to a shift in project types and the new facility not being fully operational yet.

09:35 28 Mar 2024 CDMO

Why Is Avid Bioservices (CDMO) Stock Down 18% Today?

Avid Bioservices (NASDAQ: CDMO ) stock is falling on Friday following the release of its earnings report for its fiscal second quarter of 2024. Avid Bioservices reported adjusted earnings per share of -12 cents alongside revenue of $25.4 million.

09:54 28 Mar 2024 CDMO

CDMO Stock Earnings: Avid Bioservices Misses EPS, Misses Revenue for Q2 2024

Avid Bioservices (NASDAQ: CDMO ) just reported results for the second quarter of 2024. Avid Bioservices reported earnings per share of -12 cents.

09:44 28 Mar 2024 CDMO

Avid Bioservices, Inc. (CDMO) Q2 2024 Earnings Call Transcript

Avid Bioservices, Inc. (NASDAQ:CDMO ) Q2 2024 Earnings Conference Call December 7, 2023 4:30 PM ET Company Participants Tim Brons - Investors Relations Group Nick Green - President and CEO Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Max Smock - William Blair Thomas Kelliher - RBC Capital Markets Operator Good day, ladies and gentlemen. And welcome to the Avid Bioservices Second Quarter Fiscal 2024 Financial Results Conference Call.

06:48 28 Mar 2024 CDMO

Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates

Avid Bioservices (CDMO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.01 per share a year ago.

04:05 28 Mar 2024 CDMO

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023

TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2024 on December 7, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.

11:17 28 Mar 2024 CDMO

Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround

Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

08:45 28 Mar 2024 CDMO

From laggards to leaders: Small caps on the rise

Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, but also Royal Caribbean Cruises Ltd. NYSE: RCL and PulteGroup Inc. NYSE: PHM.

05:16 28 Mar 2024 CDMO

Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?

Avid Bioservices (CDMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CDMO Financial details

Company Rating
Buy
Market Cap
425.6M
Income
-11.45M
Revenue
140.94M
Book val./share
2.91
Cash/share
0.5
Dividend
-
Dividend %
-
Employees
365
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-34.69
Forward P/E
-116.33
PEG
3.2
P/S
2.82
P/B
2.16
P/C
13.96
P/FCF
-7.11
Quick Ratio
0.72
Current Ratio
1.35
Debt / Equity
1.06
LT Debt / Equity
1.06
-
-
EPS (TTM)
-0.18
EPS next Y
-0.06
EPS next Q
-0.03
EPS this Y
-99.52%
EPS next Y
-64.93%
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
22.73%
Revenue Q/Q
-32.69%
EPS Q/Q
350.45%
-
-
-
-
SMA20
-12.26%
SMA50
7.42%
SMA100
6.08%
Inst Own
74.33%
Inst Trans
0.71%
ROA
-3%
ROE
-6%
ROC
-0.03%
Gross Margin
13%
Oper. Margin
-8%
Profit Margin
-8%
Payout
-
Shs Outstand
63.24M
Shs Float
62.58M
-
-
-
-
Target Price
-
52W Range
4.07-21.05
52W High
-66.76%
52W Low
+74.5%
RSI
50.28
Rel Volume
0.51
Avg Volume
1.39M
Volume
712.33K
Perf Week
5.76%
Perf Month
4.49%
Perf Quarter
-26.37%
Perf Half Y
-27.89%
-
-
-
-
Beta
1.653
-
-
Volatility
0.13%, 0.73%
Prev Close
2.8%
Price
6.98
Change
0%

CDMO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-04-30

Metric History 2019-04-302020-04-302021-04-302022-04-30 2023-04-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.961.061.651.722.4
Net income per share
-0.08-0.130.191.840.01
Operating cash flow per share
-0.210.10.540.14-0.21
Free cash flow per share
-0.230.040.37-0.68-1.45
Cash per share
0.580.652.921.820.62
Book value per share
0.950.751.342.513.04
Tangible book value per share
0.950.751.322.513.04
Share holders equity per share
0.950.751.342.513.04
Interest debt per share
00.482.052.673.08
Market cap
268.15M342.32M1.25B934.28M1.11B
Enterprise value
235.89M332.91M1.19B990.64M1.26B
P/E ratio
-63.62-47.18111.157.321.97K
Price to sales ratio
55.73137.817.41
POCF ratio
-23.1358.7539.9798.71-85.81
PFCF ratio
-20.47169.8958.46-19.9-12.22
P/B Ratio
5.058.1716.035.355.84
PTB ratio
5.058.1716.035.355.84
EV to sales
4.45.5812.468.288.42
Enterprise value over EBITDA
-41.96-32.5496.5264.57272.99
EV to operating cash flow
-20.3457.1338.31104.66-97.51
EV to free cash flow
-18.01165.2256.03-21.1-13.88
Earnings yield
-0.02-0.020.010.140
Free cash flow yield
-0.050.010.02-0.05-0.08
Debt to equity
0.070.641.521.051
Debt to assets
0.050.250.450.420.42
Net debt to EBITDA
5.740.92-4.183.6732.74
Current ratio
2.221.342.932.381.53
Interest coverage
1.45-1.32K7.674.05-1
Income quality
2.75-0.562.780.07-23.01
Dividend Yield
0.020.01000
Payout ratio
-1.03-0.60.400
Sales general and administrative to revenue
00.240.170.170.18
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.13-0.65-0.32-5.966.02
Capex to revenue
-0.03-0.06-0.1-0.47-0.52
Capex to depreciation
-0.55-1.23-2.86-12.59-10.77
Stock based compensation to revenue
0.030.040.040.060.07
Graham number
1.271.472.4110.20.78
ROIC
-0.09-0.080.050.270
Return on tangible assets
-0.05-0.070.040.30
Graham Net
0.34-0.270.12-1.39-2.89
Working capital
28.16M15.28M136.87M104.26M38.74M
Tangible asset value
53.07M41.9M76.84M174.88M189.82M
Net current asset value
25.99M-5.96M20.03M-75.29M-149.13M
Invested capital
0.070.641.521.051
Average receivables
7.73M11.8M18.43M25.44M26.91M
Average payables
3.13M5.14M7.59M9.38M17.05M
Average inventory
11.34M8.72M11.38M18.97M34.99M
Days sales outstanding
79.6872.7995.0179.0968.24
Days payables outstanding
34.2538.7850.7641.8276.21
Days of inventory on hand
51.671.2365.1114.68136.06
Receivables turnover
4.585.013.844.615.35
Payables turnover
10.669.417.198.734.79
Inventory turnover
7.075.125.613.182.68
ROE
-0.08-0.170.140.730
Capex per share
-0.03-0.07-0.17-0.81-1.25

Quarterly Fundamentals Overview

Last date of statement is 2023-10-31 for Q2

Metric History 2022-10-312023-01-312023-04-302023-07-31 2023-10-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.560.610.640.60.4
Net income per share
-0.020.010-0.03-0.15
Operating cash flow per share
-0.06-0.110.0400.1
Free cash flow per share
-0.61-0.29-0.35-0.23-0.02
Cash per share
1.240.960.620.40.5
Book value per share
2.912.973.033.032.91
Tangible book value per share
2.912.973.033.032.91
Share holders equity per share
2.912.973.033.032.91
Interest debt per share
2.932.913.042.993.11
Market cap
1.05B987.6M1.11B795.53M388.37M
Enterprise value
1.16B1.11B1.26B959.58M552.24M
P/E ratio
-227.88535.58-899.31-95.02-10.21
Price to sales ratio
30.3225.9827.9321.0915.29
POCF ratio
-281.97-142.82397.12-2.86K63.68
PFCF ratio
-27.55-54.13-50.35-55.28-317.29
P/B Ratio
5.825.335.874.172.11
PTB ratio
5.825.335.874.172.11
EV to sales
33.3129.1631.7225.4421.75
Enterprise value over EBITDA
-1.61K218.751.05K-443.63-66.55
EV to operating cash flow
-309.83-160.29450.96-3.45K90.55
EV to free cash flow
-30.27-60.76-57.17-66.67-451.17
Earnings yield
0000-0.02
Free cash flow yield
-0.04-0.02-0.02-0.020
Debt to equity
10.9710.991.06
Debt to assets
0.410.40.420.430.43
Net debt to EBITDA
-144.5823.85124.85-75.84-19.75
Current ratio
1.771.521.531.531.35
Interest coverage
-3.824.38-0.892.79-13.94
Income quality
3.23-15-9.060.13-0.64
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000.1700
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
9.231.64-8.8950.77-1.2
Capex to revenue
-0.99-0.3-0.63-0.37-0.29
Capex to depreciation
-18.97-5.91-13.2-5.33-2.63
Stock based compensation to revenue
0.080.070.090.060.1
Graham number
1.10.70.581.513.14
ROIC
0000-0.02
Return on tangible assets
0000-0.02
Graham Net
-2.31-2.62-2.88-3.09-3.2
Working capital
63.56M45.02M38.74M34.26M27.27M
Tangible asset value
181.55M185.75M189.82M190.95M183.68M
Net current asset value
-114.71M-132.69M-149.13M-153.42M-166.76M
Invested capital
10.9710.991.06
Average receivables
30.07M26.16M26.56M22.06M20.22M
Average payables
26.89M29.86M30.49M23.7M22.8M
Average inventory
34.71M42.08M44.51M42.39M39.72M
Days sales outstanding
70.1959.6963.1138.6785.86
Days payables outstanding
68.59116.1770.4761.0668.22
Days of inventory on hand
114.85143.98125.82109.38115.52
Receivables turnover
1.281.511.432.331.05
Payables turnover
1.310.771.281.471.32
Inventory turnover
0.780.630.720.820.78
ROE
-0.0100-0.01-0.05
Capex per share
-0.55-0.18-0.4-0.22-0.12

CDMO Frequently Asked Questions

What is Avid Bioservices, Inc. stock symbol ?

Avid Bioservices, Inc. is a US stock , located in Tustin of Ca and trading under the symbol CDMO

What is Avid Bioservices, Inc. stock quote today ?

Avid Bioservices, Inc. stock price is $6.98 today.

Is Avid Bioservices, Inc. stock public?

Yes, Avid Bioservices, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap